HemaSphere (Aug 2023)
P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
- Paolo Strati,
- Lei Feng,
- Jason Westin,
- Ranjit Nair,
- Sushanth Gouni,
- Luis Fayad,
- Maria Rodriguez,
- Dai Chihara,
- Luis Malpica,
- Raphael Steiner,
- Mariana Gallardo,
- Loretta J. Nastoupil,
- Sattva Neelapu
Affiliations
- Paolo Strati
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Lei Feng
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Jason Westin
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Ranjit Nair
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Sushanth Gouni
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Luis Fayad
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Maria Rodriguez
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Dai Chihara
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Luis Malpica
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Raphael Steiner
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Mariana Gallardo
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Loretta J. Nastoupil
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- Sattva Neelapu
- 1 The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, United States
- DOI
- https://doi.org/10.1097/01.HS9.0000971264.63302.14
- Journal volume & issue
-
Vol. 7
p. e6330214
Abstract
No abstracts available.